In the fireside chat, Dr. Rhew described how AI-driven modeling and simulation are drastically reducing the time required to identify and develop drug candidates. He provided an example where a ...

COUR Pharmaceuticals has been around a while, but not until last year did the company solidify behind its ultimate mission ...

Many venture industry observers have wondered whether Andreessen Horowitz, a firm that manages $45 billion, has its sights on ...

Year-over-year BioSpace data show there were fewer job postings live on the website in the fourth quarter of 2024, and the ...

Few know this better than Evgeny Oystacher, a veteran entrepreneur with over 25 years of experience in global markets and ...

Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...

Detailed price information for Tevogen Bio Holdings Inc (TVGN-Q) from The Globe and Mail including charting and trades.

Good morning, and welcome to the Bio-Techne Earnings Conference Call for the Second Quarter of Fiscal Year 2025. At this time, all participants have been placed in a listen-only mode and the call will ...

We recently published a list of 10 Best Mid-Cap Growth Stocks to Buy According to Analysts. In this article, we are going to ...

was you have to be a clinical-asset company (to get funding),” said Jodi Cook, president and CEO of Skylark Bio ... churn of M&A news around the J.P. Morgan Healthcare Conference last ...

With another JP Morgan in the rearview mirror ... Andrew Obershain, CEO of bluebird bio, said as much on stage. A year before the FDA approved his company’s gene therapy for sickle cell ...

Bengaluru’s Aecoz, owned by Dhanvita Sathyanand, Srinidhi Rajaram, and Bharath Sathyanand, is proving that sustainable ...